Acute Limb Ischemia From Atrial Fibrillation: Catheter-Directed Thrombolysis or Surgical Thromboembolectomy?
His leg is salvageable but the clock matters — and the choice between dissolving the clot over hours or removing it surgically within the hour turns on how much time his own collateral circulation actually provides.
W.H., a 68-year-old retired man, has had atrial fibrillation for two years and was prescribed a direct oral anticoagulant to go with it — a prescription he admits, without much prompting, that he stopped filling several months ago, when the co-pay felt like more than he wanted to justify for a pill he'd never noticed doing anything. Sudden, severe pain began in his right leg six hours ago, and he was in the emergency department within ninety minutes of onset — the leg pale and cool from the mid-thigh down, an exam his vascular team read immediately as acute limb ischemia — almost certainly embolic, almost certainly originating from the atrial fibrillation he stopped treating.
His leg is threatened rather than merely viable: he has minimal sensory loss confined to the toes and no motor weakness, but his pedal arterial Doppler signals are inaudible with venous signals still present — the combination that defines Rutherford IIa, where the limb can still be salvaged but the clock matters. Had his arterial signals remained audible with fully intact sensation, he would be Rutherford I, and no urgent revascularization would be indicated at all. That classification is what actually drives the decision in front of his team, more than the embolic source itself. Catheter-directed thrombolysis, delivering a thrombolytic drug directly into the clot through a catheter, can restore flow without the morbidity of open surgery, but it works over hours, not minutes, and requires a limb sturdy enough to tolerate that delay. Surgical thromboembolectomy is faster and more definitive but carries its own operative risk and morbidity. For a viable-but-threatened limb like his, six hours into symptoms, the two options are genuinely competitive, and the choice turns on how much time his leg's collateral circulation can actually buy. He has no history of recent surgery, stroke, or bleeding that would categorically rule out thrombolysis, and no absolute contraindication either way — which leaves this a genuine judgment call rather than one dictated by his other medical history.
In the emergency department, six hours in
Rutherford IIa buys us real time, but not unlimited time, and I want to be direct about the tradeoff: surgical thromboembolectomy restores flow within the hour, definitively, versus catheter-directed thrombolysis, which works over several hours and requires serial reassessment to confirm the limb is tolerating the wait. Given that his leg's collateral flow is currently adequate to preserve motor function and all but toe-level sensation, I think thrombolysis is a reasonable first approach, but only if we're honest that surgery becomes the fallback the moment his exam shows any deterioration, not a backup we're not really prepared to act on quickly.
If he were Rutherford IIb — sensory loss extending above the toes with rest pain, or any motor weakness — I wouldn't be offering thrombolysis as a stand-alone option at all; that tier needs immediate revascularization, not a therapy that works over hours. Minimal toe-level numbness like his is still IIa, which is the distinction the whole plan turns on.
From the atrial fibrillation side, I want to flag that whichever revascularization strategy is chosen, his underlying problem — untreated AF — caused this and will cause it again if it isn't actually addressed afterward. His non-adherence to his DOAC wasn't a one-time lapse; it was a cost barrier he never brought up until this happened. I'd want a real conversation about a different, more affordable anticoagulant or a patient-assistance program before he leaves, not just a prescription refill that repeats the same gap.
I'm not suggesting that changes today's acute decision between thrombolysis and surgery — it doesn't. I'm flagging it because whichever limb-salvage strategy succeeds today, the actual long-term stroke and recurrent-embolism prevention depends on solving the adherence problem, not just the clot.
On the acute decision: catheter-directed thrombolysis with a tissue plasminogen activator is a reasonable choice given his Rutherford IIa classification and absence of bleeding contraindications, but it needs to come with a defined reassessment schedule — limb exam and Doppler signals checked at intervals, not just infused and left to run its course. If his exam shows any deterioration at any reassessment, that's an immediate trigger to move to surgical thromboembolectomy rather than continuing thrombolysis on its original timeline.
Agreed: catheter-directed thrombolysis started with heparin, defined reassessment intervals set for limb exam and Doppler signals, and an immediate trigger to convert to surgical thromboembolectomy if any deterioration appears.
Thrombolysis continues on its original timeline, sparing him open surgical morbidity.
Surgical thromboembolectomy proceeds immediately, without waiting for the thrombolysis timeline to complete.
Before discharge, his anticoagulation gap will be addressed directly — a different agent or a cost-assistance program, not just a repeat of the prescription he stopped filling.